Tvardi Therapeutics
TVRD
121 hedge funds and large institutions have $262M invested in Tvardi Therapeutics in 2017 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 24 closing their positions.
0.07% less ownership
Funds ownership: 1.7% → 1.63% (-0.07%)
5% less funds holding
Funds holding: 127 → 121 (-6)
15% less capital invested
Capital invested by funds: $307M → $262M (-$45.1M)
17% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 24
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
38% less call options, than puts
Call options by funds: $7.1M | Put options by funds: $11.4M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$5.1M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$2.64M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.83M |
| 4 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$1.76M |
| 5 |
BlackRock
New York
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.91M |
| 2 |
Morgan Stanley
New York
|
-$4.83M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.27M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.58M |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$2.19M |
TVRD Hedge Fund Activity: Q3 2017 in Review
121 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2017, worth a combined $262M — down 15% from $307M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TVRD and 20 opened new positions — a net loss of 4 holders — while 40 trimmed existing stakes and 33 added.
The largest buyer was State Street, adding an estimated $5.1M. The largest seller was Balyasny Asset Management, cutting an estimated $5.91M.
- 121 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2017, down from 127 in Q2 2017.
- Funds reported $262M of Tvardi Therapeutics stock for Q3 2017, down 15% quarter-over-quarter.
- 20 funds opened new Tvardi Therapeutics positions in Q3 2017 and 24 closed out, a net change of -4 holders.
- The largest Tvardi Therapeutics buyer in Q3 2017 was State Street, an estimated $5.1M added.
- The largest Tvardi Therapeutics seller in Q3 2017 was Balyasny Asset Management, an estimated $5.91M sold.
Based on aggregated 13F filings for Q3 2017.